Chiesi Global Rare Diseases and Arbor Biotechnologies launched a collaboration to develop an in vivo CRISPR‑based therapy targeting primary hyperoxaluria type 1 (PH1), with Chiesi committing up to $115 million to the program. The alliance marks Chiesi’s entry into genetic medicines and pairs its rare‑disease commercialization expertise with Arbor’s in vivo gene‑editing platform. Under the deal, Arbor will advance its lead in vivo editing candidate toward IND‑enabling studies while Chiesi will fund development and retain certain commercialization rights. The partnership underscores growing big‑pharma interest in programmable in vivo genome editors for monogenic liver disorders where single‑dose editing could be transformative. Stakeholders noted the scientific and regulatory complexities for in vivo gene editing — delivery, off‑target assessment and durable efficacy — and pointed to the partnership as a risk‑sharing model increasingly favored by both startups and established rare‑disease companies.